Choudhury clarified that similar exemptions were also given by the ministry of environment and forests in 2006 for rDNA pharma products from the GMO regulatory system after primary evaluation by a review committee of the Department of Bio-Technology.
These pharma products are subsequently regulated by the Drug Controller General of India (DGCI).
“I feel that biosafety issues need to be properly addressed before any such regulatory oversight is relaxed. This is because even in gene editing where no foreign material is used, we are tampering with the natural gene,” Dr G V Ramanjaneyulu, executive director of the Centre for Sustainable Agriculture (CSA) told Business Standard.